Rational Peptide Design Platform

for Next-Gen Biologics

The Precision & Safety advantage


Peptide-based technologies are revolutionizing various fields, significantly impacting both productivity and therapeutic applications

At Splinter Biotech, we are moving beyond the traditional "hit-or-miss" drug discovery. Our Rational Peptide Design Platform leverages Molecular Docking and RFdiffusion to predict protein interactions with unprecedented accuracy.

By focusing on specific G-protein-coupled receptors, we trigger targeted physiological effects—such as increasing lean muscle mass or reducing liver fat—without the systemic toxicity often found in small molecules. We are building a high-throughput factory of protected biological assets, designed to be licensed by Tier-1 Pharma as validated, de-risked solutions.

Why It’s the Future of Biotech

We are at the tipping point of a new era in programmable medicine. Traditionally, discovering a functional peptide was like finding a needle in a haystack. Today, we are building the needle.

The Peptide Synthesis Workflow.

How Peptides Work — Splinter Biotech
Step 01 / 05
Amino Acid Building Blocks
Peptides are short chains of amino acids — the fundamental molecular units that determine biological function.
00:00 / 00:25
Splinter Biotech — Peptide Development Pipeline
Peptide Development Pipeline
29
Total assets
Under PCT patent
9
TRL 4 — Validated
Lab-scale proof of concept
20
TRL 3 — Experimental
Analytical proof of concept
2
Impact areas
Veterinary & human health
TRL 3 — 20 assets (69%)
TRL 4 — 9 assets (31%)
Discovery
Characterization
TRL 3 — Proof of Concept
TRL 4 — Lab Validation
Human health
Scaffold
design
In silico
screening
12
assets
PCT patent Human
5
assets
PCT patent Human
Veterinary
Scaffold
design
In silico
screening
8
assets
PCT patent Veterinary
4
assets
PCT patent Veterinary
All 29 peptide assets are protected under PCT international patent applications. TRL 3 denotes experimental proof of concept with analytical validation; TRL 4 denotes laboratory-scale validation of performance in a relevant environment.

29 Peptides in Our Veterinary and Human Therapeutics Pipeline

Recognizing the complexities of innovation and new technology development, we champion a collaborative approach to achieve significant results and impact. Our strategy is strengthened by key partnerships: access to cutting-edge scientific equipment through the MELISA Institute's core facility (featuring advanced proteomics and genomics capabilities), robust intellectual property protection with Santa Cruz IP.

Collaboration

Team & Founders

  • Mauricio Hernandez

    Co Founder & CSO

    Biochemist ,MSc Microbiology, Proteomics Specialist.

    PhD (Student) Clinical Applied Sc.

    Vanderbilt University, Universidad Austral, Universidad de Concepción.

    +100 Peptides designed. Senior experience in research, biotech innovations and scientific publications.

  • Patricio Pizarro

    Co Founder & Financial Lead

    Commercial Engineer,Private Equity Graduate.

    University of Oxford, Universidad Austral.

    +15 years of experience in tech transfer and early stage investment. 

    4X founder, 2 Startup investor and board member in Biotech and Data Analytics sector.

  • Cristian Placencia

    Co Founder

    Pharmacist, MBA.

    Universidad del Desarrollo, Universidad de Concepción.

    2X Pharmaceutical company General Manager.

    Senior experience industry in general management, sales, commercials and growth strategy.

  • Jorge Becar

    Co Founder & Legal Lead.

    Lawyer, Master of Laws

    Universidad de Concepción, Edinburgh University.

    Partner in Becar & Becar Law Office. Senior experience in Intellectual Property, Taxes, International Trade and Investment.

  • Felipe Reyes

    Co Founder

    Pharmacist, MBA, MHA

    Universidad Austral, Universidad Católica, Universidad del Desarrollo

    Senior experience as manager in the pharmaceutical industry in marketing, business development and market access.

Let’s dive deeper